BioCytics
Huntersville, US · Delaware corporation
BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 3 rounds · 2023–2026
▶$25KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John PowderlyExecutive Officer, Director
- Jim PowderlyExecutive Officer
- Offering amount
- $7M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25KraisedDec 2023 · 1 investors · Other Health CareRule 506(b)
▶$25KraisedDec 2023 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Don L. JacksonExecutive Officer
- Jim PowderlyExecutive Officer
- John PowderlyExecutive Officer, Director
- Stacy PowderlyExecutive Officer
- Offering amount
- $4M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedMar 2023 · 18 investors · Other Health CareRule 506(b)
▶$1.4MraisedMar 2023 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John PowderlyExecutive Officer, Director
- Matthew PietrasExecutive Officer
- Jim PowderlyExecutive Officer
- Offering amount
- $8M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does BioCytics do?
- BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
- Who founded BioCytics?
- BioCytics was founded by John Powderly.
- How much funding has BioCytics raised?
- BioCytics has disclosed $1.4M raised across 3 rounds.
- Where is BioCytics headquartered?
- BioCytics is headquartered in Huntersville, US.